These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37969817)

  • 41. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
    Lee EW; Khan S
    Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
    Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
    Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.
    Chen QF; Jia ZY; Yang ZQ; Fan WL; Shi HB
    Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1748-1755. PubMed ID: 28681222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
    Li H; Wu F; Duan M; Zhang G
    Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization.
    Pipa-Muñiz M; Sanmartino S; Mesa A; Álvarez-Navascués C; González-Diéguez ML; Cadahía V; Rodríguez JE; Vega F; Rodríguez M; Costilla-García SM; Varela M
    BMC Gastroenterol; 2020 Jun; 20(1):166. PubMed ID: 32487071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
    Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
    J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
    Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
    Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma.
    Chai NX; Chapiro J; Petukhova A; Gross M; Kucukkaya A; Raju R; Zeevi T; Elbanan M; Lin M; Perez-Lozada JC; Schlachter T; Strazzabosco M; Pollak JS; Madoff DC
    Clin Imaging; 2021 Aug; 76():123-129. PubMed ID: 33592550
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Bzeizi KI; Arabi M; Jamshidi N; Albenmousa A; Sanai FM; Al-Hamoudi W; Alghamdi S; Broering D; Alqahtani SA
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
    Zhu D; Yuan D; Wang Z; Chen S
    Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation.
    Kluger MD; Halazun KJ; Barroso RT; Fox AN; Olsen SK; Madoff DC; Siegel AB; Weintraub JL; Sussman J; Brown RS; Cherqui D; Emond JC
    Liver Transpl; 2014 May; 20(5):536-43. PubMed ID: 24493271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. D-dimer for assessment of treatment response, and survival to drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.
    Duan Y; Hou X; Guo J; Li H; Cai L; Cheng L; Zhao W; Shao X; Du H; Diao Z; Li C
    Clin Res Hepatol Gastroenterol; 2023 Apr; 47(4):102096. PubMed ID: 36801385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres
    Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S
    Front Oncol; 2021; 11():793581. PubMed ID: 35127501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intraarterial Therapies for the Management of Hepatocellular Carcinoma.
    Garg T; Shrigiriwar A; Habibollahi P; Cristescu M; Liddell RP; Chapiro J; Inglis P; Camacho JC; Nezami N
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
    Li N; Chen J
    Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.